In the current manuscript, we demonstrated the capability of our migration-based device to isolate TICs in triple negative breast cancer (TNBC), which encompasses molecular subtypes lacking expression of estrogen receptor (ER), progesterone receptor (PR), and amplification of Her2. Here, PGR is linked to triple-negative breast carcinoma.